BRCA1 and ovarian cancer: One clinical trial (SOLO2/ENGOT-Ov21) demonstrated that olaparib provided a median OS benefit of 12.9 months compared with placebo in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation [30].